CardioWise

Executive Summary

CardioWise is a private U.S.-based company developing a non-invasive Cardiac Computed Tomography (CT) analysis software that leverages AI to create 3D models of the human heart. Founded in 2013 and headquartered in Fayetteville, Arkansas, the company aims to improve early and accurate diagnosis of heart disease—a leading cause of death worldwide. By converting standard CT scans into intuitive 3D images, CardioWise's technology enables clinicians to assess cardiac structure and function without invasive procedures, potentially reducing diagnostic delays and improving patient outcomes. The platform addresses a critical gap in cardiovascular care, where timely and precise diagnosis is essential for preventing disease progression.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) Clearance for Expanded Indication (e.g., coronary artery disease assessment)70% success
• Q2 2027Strategic Partnership with Major Hospital Network or Imaging OEM60% success
• Q4 2026Publication of Clinical Validation Study in Peer-Reviewed Journal80% success